Twist Bioscience Corp
TWST
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
84.5% downsideOvervalued by 84.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.16 Billion |
|---|---|
| Enterprise Value | $4.14 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.3 |
| Beta | 2.23 |
| Outstanding Shares | 61,702,000 |
Return
| Return on Equity | -17.86% |
|---|---|
| Return on Assets | -12.02% |
| Return on Invested Capital | -24.48% |
Valuation & Multiples
| P/E Ratio | -50.77 |
|---|---|
| PEG | -425.42 |
| Price to Sales | 12.06 |
| Price to Book Ratio | 10.33 |
| Enterprise Value to Revenue | 10.1 |
| Enterprise Value to EBIT | -30.38 |
| Enterprise Value to Net Income | -51 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5164▼ 29.56% |
|---|---|
| Total Calls | 222,300▲ 83.26% |
| Total Puts | 114,800▲ 16.55% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 126.08%▲ 3.28% |
|---|---|
| Total Invested | $3.66B▲ 53.73% |
| Investors Holding | 284▲ 34.00% |
ESG Score
No data
About Twist Bioscience Corp
CEO: Emily Leproust Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary techno...
Relevant Senate Committees
Subcommittees determine the specific cash flow for science and defense agencies, which funds the research projects Twist's customers rely on.
Regulates the FDA and NIH; NIH funding levels directly impact Twist’s academic and clinical customer base and market demand.
Directly authorizes DARPA and biodefense funding, which are critical revenue and R&D drivers for synthetic biology and biosecurity applications.
Members receive classified briefings on bioweapons and global biosecurity threats, creating high informational asymmetry regarding the regulation of DNA synthesis platforms.